Description
L-carnibol (L-Carnitine) 5 mL Injection
L-carnibol is identified as a levocarnitine (L-carnitine) injection. Levocarnitine is a carnitine replacement medicine used to correct carnitine deficiency in selected clinical settings. The verified injectable product description matches levocarnitine injection, USP.
Active Ingredient and Medicine Class
Active ingredient: levocarnitine (L-carnitine). It is a naturally occurring compound involved in fatty-acid transport and energy metabolism. As a medicine, it is used as a carnitine replacement therapy.
Established Medical Uses
Official labeling for levocarnitine injection describes use in the acute and chronic treatment of patients with an inborn error of metabolism that results in secondary carnitine deficiency, and for the prevention and treatment of carnitine deficiency in patients with end-stage renal disease undergoing dialysis. The FDA label also notes use in certain inherited metabolic disorders associated with toxic organic acid accumulation.
How It Works
Levocarnitine helps transport long-chain fatty acids into mitochondria, where they can be used to produce energy. In carnitine deficiency, replacement may restore deficient carnitine levels and help the body clear excess acyl groups by forming acylcarnitines that are excreted.
Important Safety Information
FDA labeling lists no known contraindications. Important precautions relate to use in patients with metabolic disorders or dialysis-related deficiency, where the underlying condition should be considered when evaluating symptoms. Clinically significant interactions are not prominent in the official label, but the product should still be reviewed against a patient’s full medicine list and metabolic history by a healthcare professional.
Possible Side Effects
Reported adverse effects with levocarnitine include gastrointestinal symptoms such as nausea, vomiting, abdominal discomfort and diarrhea, as well as a body odor described as “fishy.” Less common but important reactions can include hypersensitivity reactions, seizures in susceptible patients, and reactions related to infusion or injection use.
Scientific Evidence
Clinical reviews and meta-analyses in hemodialysis populations show that levocarnitine can raise carnitine levels and may improve selected outcomes such as anemia response, hypotension, muscle symptoms or some cardiac measures in some studies, but the overall evidence is mixed and benefits are not uniform across all patients.
Medical Information Notice
This summary is for educational purposes only and is based on sources available at the time of review. It does not replace the official patient information leaflet or an individual assessment by a qualified healthcare professional.
Medical Sources
- U.S. FDA — CARNITOR (levocarnitine) Injection, prescribing information
- DailyMed — Levocarnitine Injection, USP
- Brian Schreiber — “Levocarnitine and dialysis: a review.” Nutr Clin Pract. 2005. PubMed
